| 摘要 |
A new pharmaceutical composition (A) contains an active agent combination of (a) at least one insulin secretion stimulant and (b) at least one 5-aryloxyalkyl-thiazolidine-2,4-dione compound (I). A new pharmaceutical composition (A) contains (in addition to one or more excipients) an active agent combination of: (a) at least one insulin secretion stimulant; and (b) at least one thiazolidinedione compound of formula (I). A = 2-16C saturated or unsaturated, linear or branched hydrocarbylene; D1 = mono-, bi- or tricyclic, carbocyclic or heterocyclic aromatic residue (optionally containing one or more heteroatoms); X = H, 1-6C alkyl, 1-6C alkoxy, (1-6C) alkoxy-(1-6C) alkyl, aryl, optionally substituted aryl-(1-6C) alkyl, aryl-(1-6C) alkyl-aryl, halo, CF3, CN, OH, NO2, NH2, COOH, alkoxycarbonyl, carboxamide, sulfonyl, sulfone, sulfonamide, sulfamoyl, alkylsulfonylamino, acylamino or OCF3; n = 1-3; aryl moieties in X = mono- or bicyclic aryl (optionally containing 1 or 2 heteroatoms), e.g. phenyl or alpha - or beta -naphthyl; provided that if A = butyl then -D1-(X)n is not 4-chlorophenyl. An Independent claim is included for the use of (a) in combination with (b) for the production of a combined medicament for treating diabetes.
|
